Edition:
United States

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

197.78USD
17 Oct 2017
Change (% chg)

$-0.63 (-0.32%)
Prev Close
$198.41
Open
$199.01
Day's High
$203.86
Day's Low
$197.44
Volume
925,610
Avg. Vol
499,992
52-wk High
$256.78
52-wk Low
$184.58

Chart for

About

Allergan plc is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US... (more)

Overall

Beta: 1.16
Market Cap(Mil.): $66,329.69
Shares Outstanding(Mil.): 334.31
Dividend: 0.70
Yield (%): 1.41

Financials

  Industry Sector
P/E (TTM): -- 31.57 16.82
EPS (TTM): -- -- --
ROI: -- 14.96 11.24
ROE: -- 16.23 15.07

Allergan ruling casts doubt on tribal patent strategy

A U.S. judge’s ruling on Monday invalidating Allergan Plc's patents on its blockbuster $1.5 billion dry-eye medicine, Restasis, has cast doubt on the company's novel strategy to enlist a Native American tribe to help shield those patents from challenge by generic drugmakers, legal experts said.

6:06pm EDT

BRIEF-Syndax Pharmaceuticals says ‍expands pipeline with exclusive worldwide license to Allergan's portfolio of Menin-MLL inhibitors​

* Syndax Pharmaceuticals Inc - ‍expands pipeline with exclusive worldwide license to Allergan's portfolio of Menin-MLL inhibitors​

8:08am EDT

BRIEF-Syndax Pharma enters into license agreement with unit of Allergan

* On Oct 13, co entered into license agreement with Vitae Pharmaceuticals, a subsidiary of Allergan Plc​ - SEC filing

7:53am EDT

BRIEF-‍Mylan invalidates Allergan's patents on Restasis​

* U.S. district court for Eastern District of Texas issued decision finding asserted claims of patents relating to Restasis invalid ​

Oct 16 2017

U.S. judge in Texas invalidates Allergan patents on Restasis

A U.S. judge on Monday invalidated patents on Allergan Plc's dry-eye medicine Restasis on grounds that the patents cover ideas that are obvious, sending shares of the pharmaceutical company down 3.5 percent.

Oct 16 2017

UPDATE 3-U.S. judge in Texas invalidates Allergan patents on Restasis

Oct 16 A U.S. judge on Monday invalidated patents on Allergan Plc's dry-eye medicine Restasis on grounds that the patents cover ideas that are obvious, sending shares of the pharmaceutical company down 3.5 percent.

Oct 16 2017

BRIEF-U.S. Court issues adverse decision concerning Allergan's Restasis

* U.S. District Court for the Eastern District of Texas issues adverse trial decision concerning Restasis (cyclosporine ophthalmic emulsion) 0.05% patents

Oct 16 2017

U.S. judge in Texas invalidates Allergan patents on Restasis

Oct 16 A U.S. judge on Monday invalidated patents issued to Allergan Plc on its dry eye medicine Restasis, saying they covered ideas that were too obvious to protect.

Oct 16 2017

Allergan settles with one of four companies contesting Restasis patent

Allergan Plc said on Thursday it reached a settlement with InnoPharma Inc, one of the four generic drugmakers challenging the patents for its dry eye medication Restasis in federal court.

Oct 12 2017

Allergan settles with one of four companies contesting Restasis patent

Oct 12 Allergan Plc said on Thursday it reached a settlement with InnoPharma Inc, one of the four generic drugmakers challenging the patents for its dry eye medication Restasis in federal court.

Oct 12 2017

Earnings vs. Estimates